Related Experiment Video
Updated: Feb 7, 2026

Detection of Polyfunctional T Cells in Children Vaccinated with Japanese Encephalitis Vaccine via the Flow Cytometry Technique
Published on: September 23, 2022
Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children
Kaoru Araki1, Megumi Hara2, Takeshi Tsugawa3
1Department of Preventive Medicine, Faculty of Medicine, Saga University Saga, Japan; Department of Pediatrics, Faculty of Medicine, Saga University Saga, Japan.
Insights
Rotavirus (RV) vaccination is highly effective in Japanese children, demonstrating 80% effectiveness against rotavirus gastroenteritis (RVGE). The vaccines proved effective against various RV genotypes and severe cases, offering significant protection.
Area of Science:
- Pediatric Infectious Diseases
- Vaccinology
- Public Health
Background:
- Rotavirus (RV) vaccination has been available in Japan since 2011 but is not part of the national immunization program.
- Limited data exist on the vaccine effectiveness (VE) of rotavirus vaccines among Japanese children.
Purpose of the Study:
- To evaluate the real-world effectiveness of rotavirus vaccines in Japanese children.
- To assess VE against rotavirus gastroenteritis (RVGE) across different vaccine types, age groups, and RV genotypes.
Main Methods:
- Active surveillance of gastroenteritis in children across 14 medical facilities.
- Test-negative case-control design utilizing immunochromatography for RV detection and genotyping.
- Logistic regression analysis adjusted for confounding factors to determine vaccine effectiveness.
Main Results:
- Overall VE against RVGE was 80.0% (95% CI, 72.8-85.5%).
- VE against severe RVGE requiring hospitalization or intravenous rehydration was 97.3% (95% CI, 88.8-99.3%).
- Vaccine effectiveness remained high (>70%) up to two years post-vaccination and was comparable between RV1 and RV5 vaccines against common genotypes.
Conclusions:
- Rotavirus vaccines are effective in preventing mild to severe RVGE in Japanese children.
- Vaccine effectiveness is consistent across different vaccine types, time since vaccination, and rotavirus genotypes.
Background:
Rotavirus (RV) vaccination has been available in Japan since November 2011, but is not yet part of Japan's national immunisation programs. There are insufficient data on vaccine effectiveness (VE) among Japanese children.
Methods:
Between the months of January and May in 2014 and 2015, we conducted active surveillance of gastroenteritis among children at 14 medical facilities. Rectal swabs from all patients with diarrhoea or vomiting were tested for RV by immunochromatography, and positive specimens were genotyped. Demographic data and immunisation records were obtained from a questionnaire completed by their parents/guardians or medical records. A test-negative case-control design was used to examine vaccine effectiveness (VE) using unconditional logistic regression analysis adjusted for possible confounding factors.
Results:
Among the 1519 eligible subjects (children with acute gastroenteritis symptoms aged ≥2 months to <3 y visiting medical facilities) recruited, 487 cases and 925 controls were enrolled. Cases had more severe symptoms than controls, requiring more intensive treatment, including intravenous rehydration or hospitalisation. VE against all rotavirus gastroenteritis (RVGE) was 80.0% (95% confidence interval [CI], 72.8-85.5%), and VEs against RV1 and RV5 were similar, at 80.6% (95%CI, 70.7-87.1%) for RV1 and 80.4% (95% CI, 69.1-87.6%) for RV5. Although VEs of both vaccines decreased with age, VEs against all RVGE were >70% up to 2 years after vaccination. VEs increased with severity of RVGE, and VE against severe RVGE, requiring intravenous rehydration or hospitalisation, was 97.3% (95% CI, 88.8-99.3%). VEs of RV1 and RV5 against G1P[8] and G2P[4] were comparable, at RV1, 89.8% (95% CI, 78.2-95.5%) and 78.3% (95% CI, 23.6-93.8%); and RV5, 85.8% (95% CI, 72.8-92.6%) and 88.1% (95% CI, 10.1-98.4%), respectively.
Conclusions:
Rotavirus vaccines were effective in preventing mild to severe RVGE, irrespective of vaccine type, time since vaccination, or RV genotype.
Related Concept Videos
Vaccinations
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Drug Dosing: Infants and Children
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Biological Effects of Radiation

